Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Marco-Sanz

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancers|May 16, 2023
Set Protein Is Involved in FLT3 Membrane TraffickingNerea Marcotegui, Silvia Romero-Murillo, Javier Marco-Sanz, et al.
Methods in Cell Biology|March 31, 2024
Radiotherapy protocols for mouse cancer modelEneko Garate-Soraluze, Javier Marco-Sanz, Irantzu Serrano-Mendioroz, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Environmental factors contribute to cancer therapy toxicityLindsey C Mehl, Maria Sacconi Nuñez, Javier Marco Sanz, et al.
JCI Insight|August 15, 2024
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma modelsIker Ausejo-Mauleon, Naiara Martinez-Velez, Andrea Lacalle, et al.
Molecular Therapy Oncolytics|August 11, 2022
Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcomaGuillermo Herrador-Cañete, Marta Zalacain, Sara Labiano, et al.
JCI Insight|April 8, 2022
Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomasVirginia Laspidea, Montserrat Puigdelloses, Sara Labiano, et al.
Cell Reports. Medicine|June 27, 2025
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomasSara Labiano, Javier Marco-Sanz, Iker Ausejo-Mauleon, et al.
Cancer Cell|March 24, 2026
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunitySonia Marco, Myriam Fernández, Beatriz Honorato, et al.
Neuro-Oncology|March 30, 2024
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma modelsDaniel de la Nava, Iker Ausejo-Mauleon, Virginia Laspidea, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancers|May 16, 2023
Set Protein Is Involved in FLT3 Membrane TraffickingNerea Marcotegui, Silvia Romero-Murillo, Javier Marco-Sanz, et al.
Methods in Cell Biology|March 31, 2024
Radiotherapy protocols for mouse cancer modelEneko Garate-Soraluze, Javier Marco-Sanz, Irantzu Serrano-Mendioroz, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Environmental factors contribute to cancer therapy toxicityLindsey C Mehl, Maria Sacconi Nuñez, Javier Marco Sanz, et al.
JCI Insight|August 15, 2024
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma modelsIker Ausejo-Mauleon, Naiara Martinez-Velez, Andrea Lacalle, et al.
Molecular Therapy Oncolytics|August 11, 2022
Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcomaGuillermo Herrador-Cañete, Marta Zalacain, Sara Labiano, et al.
JCI Insight|April 8, 2022
Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomasVirginia Laspidea, Montserrat Puigdelloses, Sara Labiano, et al.
Cell Reports. Medicine|June 27, 2025
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomasSara Labiano, Javier Marco-Sanz, Iker Ausejo-Mauleon, et al.
Cancer Cell|March 24, 2026
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunitySonia Marco, Myriam Fernández, Beatriz Honorato, et al.
Neuro-Oncology|March 30, 2024
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma modelsDaniel de la Nava, Iker Ausejo-Mauleon, Virginia Laspidea, et al.
Pageof 1